Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 6/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | EEF2K | O00418 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6146093 | 1.00 | KDM4E (0.59) | KDM4EALDH1A1ALDH2MAOBCYP19A1 | |
| SCHEMBL12121778 | 1.00 | KDM4E (0.59) | KDM4EALDH1A1ALDH2MAOBCYP19A1 | |
| SCHEMBL15354256 | 0.87 | ALDH1A1 (0.60) | KDM4EALDH1A1ALDH2MAOBCYP19A1 | |
| SCHEMBL15354258 | 0.87 | ALDH1A1 (0.60) | KDM4EALDH1A1ALDH2MAOBCYP19A1 | |
| SCHEMBL15354259 | 0.87 | ALDH1A1 (0.60) | KDM4EALDH1A1ALDH2MAOBCYP19A1 | |
| SCHEMBL8920465 | 0.86 | CYP19A1 (0.50) | KDM4EALDH1A1ALDH2MAOBCYP19A1 | |
| SCHEMBL12121784 | 0.86 | CYP19A1 (0.50) | KDM4EALDH1A1ALDH2MAOBCYP19A1 | |
| SCHEMBL8886067 | 0.86 | MAOB (0.57) | KDM4EALDH1A1ALDH2MAOBSLC6A2 | |
| SCHEMBL12121790 | 0.82 | MAOB (0.52) | KDM4EALDH1A1ALDH2MAOBCYP19A1 | |
| SCHEMBL7645915 | 0.82 | ALDH1A1 (0.44) | KDM4EALDH1A1ALDH2MAOBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281952-A1 | DEUTERIUM-ENRICHED TOLTERODINE | PROTIA, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20090062398-A1 | DEUTERIUM-ENRICHED TOLTERODINE | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1496045-A2 | Process of preparing tolterodine and analogues thereof as well as intermediates prepared in the process | Pharmacia AB (SE) | 2005-01-12 | — | — | EP | disclosed |
| EP-1242361-B1 | PROCESS OF PREPARING TOLTERODINE AND ANALOGUES THERE OF AS WELL AS INTERMEDIATES PREPARED IN THE PROCESS | PHARMACIA AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| US-6790998-B2 | SUCH AS 5-METHYL-3-PHENYL)-INDEN-1-ONE FOR ENANTIOSELECTIVE PREPARATION OF TOLTERODINE AND ANALOGUES/SALTS THEREOF | PHARMACIA AB (SE) | 2004-09-14 | — | — | US | disclosed |
| US-6689916-B2 | TOLTERODINE AND ANALOGUES THEREOF, AS WELL AS TO NOVEL INTERMEDIATES | PHARMACIA AB (SE) | 2004-02-10 | — | — | US | disclosed |
| US-20030204114-A1 | Useful for treating urinary incontinence; key step of present method is preparation of 3,4-dihydro-6-methyl-4-phenyl-2H-benzopyran-2-one in an enantiomerically enriched form by enantioselective reactions | ANDERSSON PHER G (SE) | 2003-10-30 | — | — | US | disclosed |
| US-20030191348-A1 | Such as 5-methyl-3-phenyl)-inden-1-one for enantioselective preparation of tolterodine and analogues/salts thereof | ANDERSSON PHER G (SE) | 2003-10-09 | — | — | US | disclosed |
| US-6566537-B2 | Tolterodine | PHARMACIA AB (SE) | 2003-05-20 | — | — | US | disclosed |
| US-20020019568-A1 | Tolterodine | ANDERSSON PHER G (SE) | 2002-02-14 | — | — | US | disclosed |
| US-6310248-B2 | ENANTIOSCLECTIVELY REDUCING THE CARBONYL FUNCTION IN OF COMPOUND; SUBJECTING TO SIGMATROPIC REARRANGEMENT TO FORM A CORRESPONDING ENANTIOMERICALLY ENRICHED COMPOUND; BAEYER-VILLIGER OXIDATION; SALT FORMATION | PHARMACIA AB (SE) | 2001-10-30 | — | — | US | disclosed |
| US-20010016669-A1 | Novel process and intermediates | PHARMACIA AB (SE) | 2001-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062398-A1 | DEUTERIUM-ENRICHED TOLTERODINE | SLC6A3, AVPR2, TBCD | KDM4E 4196/4885ALDH1A1 3032/4885ALDH2 3195/4885 |
| US-20010016669-A1 | Novel process and intermediates | CYP1B1, CYP4F3, CYP4B1 | KDM4E 1592/4885ALDH1A1 993/4885ALDH2 1580/4885 |
| US-20020019568-A1 | Tolterodine | CYP1B1, THRB, AVPR1B | KDM4E 1997/4885ALDH1A1 857/4885ALDH2 1707/4885 |
| US-20110281952-A1 | DEUTERIUM-ENRICHED TOLTERODINE | SLC6A3, AVPR2, TBCD | KDM4E 4196/4885ALDH1A1 3032/4885ALDH2 3195/4885 |
| US-20030204114-A1 | Useful for treating urinary incontinence; key step of present method is preparation of 3,4-dihydro-6-methyl-4-phenyl-2H-benzopyran-2-one in an enantiomerically enriched form by enantioselective reactions | AVPR2, AVPR1B, AVPR1A | KDM4E 504/4885ALDH1A1 671/4885ALDH2 807/4885 |
| US-20030191348-A1 | Such as 5-methyl-3-phenyl)-inden-1-one for enantioselective preparation of tolterodine and analogues/salts thereof | CYP1B1, CYP4B1, THRB | KDM4E 2073/4885ALDH1A1 543/4885ALDH2 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.